Surgerii Robotics obtains Series D funding to take single-port system global

The SHURUI SP single-port endsocopic medical system has CE authorization. Resource Surgerii Robotics

Surgerii Robotics Co. this month shut $100 million in Collection D funding. The Beijing-based business stated it will certainly make use of the financing to market its SHURUI single-port medical robotic both locally and worldwide, along with to increase the manufacturing of its next-generation items.

Single-port surgical treatment is a minimally intrusive strategy including endoscope and medical tools with a solitary laceration. Surgerii stated its SHURUI robotic makes use of snake-like tools and teleoperation innovation to aids medical professionals in accomplishing accurate procedures.

Surgerii establishes, generates, and advertises laparoscopic medical robot systems and devices. In September 2025, it got CE authorization in Europe for SHURUI. The business asserted that it was the 2nd such authorization after User-friendly Surgical obtained a CE mark for its da Vinci SP system in 2024.

Surgerii promotes medical technologies

The SHURUI single-port endoscopic medical system, or SR-ENS-600, is “the globe’s initial readily readily available single-port medical robotic with snake-like tools,” asserted Surgerii Robotics. The business kept in mind that it has actually been constructing its copyright (IP) profile.

The core innovation of the SHURUI SP robotic is based upon the “Twin Continuum System” layout created by Prof. Kai Xu of Shanghai Jiao Tong College. Surgerii stated the development allowed the growth of its adaptable tools, which can execute very complicated and accurate treatments with a solitary 1.8 centimeters (0.7 in.) laceration.

Throughout its funding round, capitalists methodically examined Sugerii’s IP, mapping the international technical and license landscape. This consisted of an in-depth relative evaluation in between SHURUI SP and greater than 3,000 legitimate, approved licenses held by leading endoscopic medical robotic business throughout Europe and the United State

Surgerii stated the evaluation located that, regardless of the very thick license landscape, its robotic “has actually accomplished turbulent development and advancements in vital innovations.” The business insisted that its strategy is substantially differentiated from existing medical licenses, giving a strong technical and lawful structure to run and market SHURUI in worldwide markets.

A mimial laceration with the navel offers gain access to for a steerable robotic. Resource: Surgerii Robotics

SHURUI authorized for grown-up, pediatric people

The SR-ENS-600 acquired advertising authorization from China’s National Medical Products Management (NMPA) in June 2023. Surgerii stated SHURUI SP was initial single-port endoscopic medical robotic to get such authorization in China.

In August 2025, the robotic obtained CE accreditation, allowing its usage throughout urology, gynecology, basic surgical treatment, and thoracic surgical treatment for both grown-up and pediatric people. Surgerii asserted it is the only CE-certified single-port medical robotic authorized for pediatric usage and the initial Chinese medical robotic to be licensed for the usage in people of any age team.

To day, the business has actually developed medical teamwork with over 70 Quality A tertiary healthcare facilities in China, executed greater than 3,000 surgical procedures, been associated with virtually 50 treatments worldwide, and created over 80 medical methods that fill up spaces in medical method throughout Asia or China. These treatments vary from pancreaticoduodenectomy for pancreatic cancer cells to surgical procedures on pediatric people as young as 7 days old.

Surgerii stated it has actually shown that its innovation can minimize medical injury while covering an also more comprehensive person populace than multi-port medical robotics. SHURUI does not yet have united state Fda authorization.

A presentation of SHURUI’s adaptable and trademarked tools managing an egg. Resource: Surgerii Robotics

Financial investment to enhance European fostering

Devoted Valley Funding, a personal equity company concentrating on health care and innovation developments, led Surgerii Robotics’ Collection round.

Various other individuals consisted of Shanghai Health care Funding, a calculated capitalist in health care section leaders; V Celebrity Funding and DNV Funding, both concentrating on health care technologies; and Hefei Industrial Financial investment, a financier with comprehensive experience and commercial sources in difficult innovation and tactical arising sectors.

Surgerii kept in mind that this financial investment came as it is strengthening its residential market infiltration and speeding up worldwide commercialization.

” Leveraging the solid assistance from this brand-new round funding, the business will certainly better the medical fostering, establish innovative power tools, consequently strengthening the healing worth of single-port robotics in even more and complicated instances, along with developing a turbulent organized remedy fixated sophisticated innovation to profit a bigger variety of people,” it specified.

In 2025, Surgerii developed the European Professional Quality Facility in partnership with IRCAD, a leading organization for minimally intrusive medical training. The business included that it has actually established its tactical concentrate on the premium European market.

The message Surgerii Robotics acquires Collection D moneying to take single-port system international showed up initially on The Robotic Record.